Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.

@article{Kim2013ClinicalRT,
  title={Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.},
  author={Kevin B Kim and Maria E Cabanillas and Alexander J Lazar and Michelle D Williams and Deborah Sanders and Joseph L Ilagan and Keith B. Nolop and Richard W. J. Lee and Steven I. Sherman},
  journal={Thyroid : official journal of the American Thyroid Association},
  year={2013},
  volume={23 10},
  pages={1277-83}
}
BACKGROUND Clinical benefit from cytotoxic chemotherapy for metastatic papillary thyroid carcinoma (PTC) is disappointing, and effective therapeutic approaches for these patients are urgently needed. Because kinase-activating mutations in the BRAF proto-oncogene commonly occur in advanced PTC, and inhibition of BRAF(V600E) has shown promising clinical activity in melanoma, BRAF inhibitor therapy may be an effective strategy to treat metastatic PTC. METHODS The dose escalation portion of a… CONTINUE READING